M. W. Ferenczy, L. J. Marshall, C. Nelson, W. J. Atwood, A. Nath et al., Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virusinduced demyelinating disease of the human brain, Clin Microbiol Rev, vol.25, pp.471-506, 2012.

J. R. Berger, A. J. Aksamit, D. B. Clifford, L. Davis, I. J. Koralnik et al., PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section, Neurology, vol.80, pp.1430-1438, 2013.

A. Fischer, J. Provot, J. Jais, A. Alcais, and N. Mahlaoui, Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies, J Allergy Clin Immunol, vol.140, pp.1388-1393, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01783653

C. Picard, B. Gaspar, H. , A. , W. Bousfiha et al., International Union of Immunological Societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity, J Clin Immunol, vol.38, pp.96-128, 2018.

R. Pérez-de-diego, V. Sancho-shimizu, L. Lorenzo, A. Puel, S. Plancoulaine et al., Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis, Immunity, vol.33, pp.400-411, 2010.

C. S. Zerbe, B. E. Marciano, R. K. Katial, C. B. Santos, N. Adamo et al., Progressive multifocal leukoencephalopathy in primary immune deficiencies: Stat1 gain of function and review of the literature, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.62, pp.986-94, 2016.

S. Haider, D. Nafziger, J. A. Gutierrez, I. Brar, N. Mateo et al., Progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia: a case report and review of reported cases, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.31, pp.20-22, 2000.

M. A. Rueger, H. Miletic, K. Dorries, C. Wyen, C. Eggers et al., Long-term remission in progressive multifocal leukoencephalopathy caused by idiopathic CD4+ T lymphocytopenia: a case report, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.42, pp.53-59, 2006.

A. Patel, J. Patel, and J. Ikwuagwu, Treatment of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia, J Antimicrob Chemother, vol.65, pp.2489-92, 2010.

A. Shekaili, L. Sheikh, F. , A. Gazlan, S. et al., Novel mutation in DOCK8-HIES with severe phenotype and successful transplantation, Clin Immunol Orlando Fla, vol.178, pp.39-44, 2017.

Z. Aschermann, E. Gomori, G. G. Kovacs, E. Pal, G. Simon et al., X-linked hyper-IgM syndrome associated with a rapid course of multifocal leukoencephalopathy, Arch Neurol, vol.64, pp.273-279, 2007.

F. Dhalla, S. Murray, R. Sadler, B. Chaigne-delalande, T. Sadaoka et al., Identification of a novel mutation in MAGT1 and progressive multifocal leucoencephalopathy in a 58-year-old man with XMEN disease, J Clin Immunol, vol.35, pp.112-120, 2015.

C. Schröder, N. T. Baerlecken, U. Pannicke, T. Dörk, T. Witte et al., Evaluation of RAG1 mutations in an, Clin Immunol Orlando Fla, vol.179, pp.1-7, 2017.

P. Maffucci, C. A. Filion, B. Boisson, Y. Itan, L. Shang et al., Genetic diagnosis using whole exome sequencing in common variable immunodeficiency, Front Immunol, vol.7, p.220, 2016.

J. De-villartay, A. Lim, H. Al-mousa, S. Dupont, J. Déchanet-merville et al., A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infection, J Clin Invest, vol.115, pp.3291-3300, 2005.
URL : https://hal.archives-ouvertes.fr/hal-00020065

E. Morelon, A. Dautry-varsat, L. Deist, F. Hacein-bay, S. Fischer et al., T-lymphocyte differentiation and proliferation in the absence of the cytoplasmic tail of the common cytokine receptor gamma c chain in a severe combined immune deficiency X1 patient, Blood, vol.88, pp.1708-1725, 1996.

C. Bozic, M. Subramanyam, S. Richman, T. Plavina, A. Zhang et al., Anti-JC virus (JCV) antibody prevalence in the JCV epidemiology in MS (JEMS) trial, Eur J Neurol, vol.21, pp.299-304, 2014.

G. Bloomgren, S. Richman, C. Hotermans, M. Subramanyam, S. Goelz et al., Risk of natalizumab-associated progressive multifocal leukoencephalopathy, N Engl J Med, vol.366, pp.1870-80, 2012.

K. L. Amend, B. Turnbull, N. Foskett, P. Napalkov, T. Kurth et al., Incidence of progressive multifocal leukoencephalopathy in patients without HIV, Neurology, vol.75, pp.1326-1358, 2010.

C. Power, J. G. Gladden, W. Halliday, D. Bigio, M. R. Nath et al., AIDS-and non-AIDS-related PML association with distinct p53 polymorphism, Neurology, vol.54, pp.743-749, 2000.

F. N. Engsig, A. Hansen, L. H. Omland, G. Kronborg, J. Gerstoft et al., Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study, J Infect Dis, vol.199, pp.77-83, 2009.

D. Gobert, J. B. Bussel, C. Cunningham-rundles, L. Galicier, A. Dechartres et al., Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients, Br J Haematol, vol.155, pp.498-508, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00820062

D. Moshous, I. Meyts, S. Fraitag, C. Janssen, M. Debré et al., Granulomatous inflammation in cartilage-hair hypoplasia: risks and benefits of anti-TNF-? mAbs, J Allergy Clin Immunol, vol.128, pp.847-53, 2011.

J. R. Berger, Classifying PML risk with disease modifying therapies, Mult Scler Relat Disord, vol.12, pp.59-63, 2017.

M. Tuccori, D. Focosi, C. Blandizzi, D. Tacca, M. Petrini et al., Re: rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials, J Natl Cancer Inst, vol.101, pp.1289-1290, 2009.

K. R. Carson, A. M. Evens, E. A. Richey, T. M. Habermann, D. Focosi et al., Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project, Blood, vol.113, pp.4834-4874, 2009.

E. S. Mol-loy, Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies, Arthritis Rheum, vol.64, pp.3043-51, 2012.

J. R. Berger, V. Malik, S. Lacey, P. Brunetta, and P. B. Lehane, Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event, J Neuro-Oncol, vol.24, pp.323-354, 2018.

A. Lavagna, M. Bergallo, M. Daperno, R. Sostegni, C. Costa et al., Infliximab and the risk of latent viruses reactivation in active Crohn's disease, Inflamm Bowel Dis, vol.13, pp.896-902, 2007.

Y. Jamilloux, F. Cohen-aubart, C. Chapelon-abric, D. Maucort-boulch, A. Marquet et al., Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients, Semin Arthritis Rheum, vol.47, pp.288-94, 2017.

N. Schmedt, F. Andersohn, and E. Garbe, Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS), Pharmacoepidemiol Drug Saf, vol.21, pp.1216-1236, 2012.

C. Mcguigan, M. Craner, J. Guadagno, R. Kapoor, G. Mazibrada et al., Stratification and monitoring of natalizumabassociated progressive multifocal leukoencephalopathy risk: recommendations from an expert group, J Neurol Neurosurg Psychiatry, vol.87, pp.117-142, 2016.

A. Laroni, C. G. Giacomazzi, L. Grimaldi, P. Gallo, M. P. Sormani et al., Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification, J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol, vol.7, pp.665-72, 2012.

R. P. Viscidi, N. Khanna, C. S. Tan, X. Li, L. Jacobson et al., JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.53, pp.711-716, 2011.

M. A. Sahraian, E. Radue, A. Eshaghi, S. Besliu, and A. Minagar, Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis, Eur J Neurol, vol.19, pp.1060-1069, 2012.

M. P. Wattjes, A. Vennegoor, M. D. Steenwijk, M. De-vos, J. Killestein et al., MRI pattern in asymptomatic natalizumabassociated PML, J Neurol Neurosurg Psychiatry, vol.86, pp.793-801, 2015.

D. B. Clifford, D. Luca, A. Deluca, A. Simpson, D. M. Arendt et al., Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases, Lancet Neurol, vol.9, pp.438-484, 2010.

A. Balduzzi, G. Lucchini, H. H. Hirsch, S. Basso, M. Cioni et al., Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient, Bone Marrow Transplant, vol.46, pp.987-92, 2011.

L. Kunschner and T. F. Scott, Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2, Neurology, vol.65, p.1510, 2005.

K. B. Alstadhaug, T. Croughs, S. Henriksen, C. Leboeuf, I. Sereti et al., Treatment of progressive multifocal leukoencephalopathy with interleukin 7, JAMA Neurol, vol.71, pp.1030-1035, 2014.

J. Gasnault, M. De-goër-de-herve, J. Michot, H. Hendel-chavez, V. Seta et al., Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy, Open Forum Infect Dis, vol.1, p.74, 2014.

D. Pavlovic, A. C. Patera, F. Nyberg, M. Gerber, and M. Liu, Progressive multifocal leukoencephalopathy: current treatment options and future perspectives, Ther Adv Neurol Disord, vol.8, pp.255-73, 2015.